Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Position Decreased by Straight Path Wealth Management

Straight Path Wealth Management reduced its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 24.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,000 shares of the company's stock after selling 16,000 shares during the period. Straight Path Wealth Management's holdings in Teva Pharmaceutical Industries were worth $768,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Golden State Wealth Management LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $54,000. Finally, Versant Capital Management Inc increased its holdings in shares of Teva Pharmaceutical Industries by 437.8% in the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after buying an additional 4,312 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research reports. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. UBS Group lowered their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $24.13.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president directly owned 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA remained flat at $17.05 during mid-day trading on Thursday. 5,550,481 shares of the company were exchanged, compared to its average volume of 10,266,065. The business has a 50-day simple moving average of $16.95 and a 200 day simple moving average of $17.40. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a market cap of $19.56 billion, a P/E ratio of -14.83, a P/E/G ratio of 0.87 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter last year, the business posted $0.48 earnings per share. The business's quarterly revenue was up 1.9% compared to the same quarter last year. Equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.